The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Why do we need registries for patients treated with CAR T therapy?

Jan 30, 2020

The Lymphoma Hub are pleased to present a series of expert interviews from the 2nd European CAR T Cell Meeting in Sitges, ES. In this video, Christian Chabannon, University of Aix-Marseille, Marseille, FR, explains why we need registries for patients treated with CAR T therapy.

Christian Chabannon explains registries will allow us to fully measure the actual medical value of this novel product and to observe the long-term effect of CARs as they were approved based on mostly phase I/II trials with a limited number of patients.

Why do we need registries for patients treated with CAR T therapy?